Moderna and Merck Personalized mRNA Cancer Vaccine Achieves Phase 3 Clinical Milestone
In a monumental breakthrough for oncology, Moderna and Merck have released Phase 3 clinical trial results for mRNA-4157 (V940), an investigational personalized neoantigen mRNA therapy. The trial evaluated patients with high-risk stage III/IV melanoma following complete surgical resection.
In a monumental breakthrough for oncology, Moderna and Merck have released Phase 3 clinical trial results for mRNA-4157 (V940), an investigational personalized neoantigen mRNA therapy. The trial evaluated patients with high-risk stage III/IV melanoma following complete surgical resection The biotech & health science details above are what the Ars Technica report is actually claiming — not a full spec sheet.
Moderna and Merck Personalized mRNA Cancer Vaccine Achieves Phase 3 Clinical Milestone. Confirm timing, pricing, and availability with Ars Technica before treating this as shipping news.
Tech Bytes is keeping a standalone URL for this biotech & health science story so it can be cited apart from the daily pulse. The claims in the lede are attributed to Ars Technica; numbers, dates, and product names should be checked there.
Get Tech Pulse Daily in Your Inbox
Join 45,000+ engineers, founders, and tech leaders receiving high-signal daily breakdowns directly from major publishers.
Zero spam. Unsubscribe anytime in one click.
When administered in combination with Keytruda immunotherapy, the personalized mRNA vaccine demonstrated a statistically significant 49% reduction in the risk of disease recurrence or death compared to Keytruda alone over a three-year follow-up period. The vaccine is custom-manufactured for each patient based on DNA sequencing of their specific tumor neoantigens.
The companies plan to submit global regulatory filings by the end of 2026, paving the way for the world first commercial personalized cancer vaccine.